touchONCOLOGY - The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials

touchPODCAST

Kandungan disediakan oleh touchpodcast. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh touchpodcast atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

4M ago 34:04

MP3•Laman utama episod

touchEXPERT OPINIONS for touchONCOLOGY

Three internationally renowned multiple myeloma experts share insights into the unmet treatment needs for patients with relapsed/refractory multiple myeloma, the rationale for emerging protein degradation and immunomodulation-based therapies, and the latest data and ongoing clinical trials for these investigational agents.

The experts

Prof. Cristina Gasparetto - Duke Cancer Institute, Durham, NC, USA
Prof. Sagar Lonial - Emory University, Atlanta, GA, USA
Prof. Sundar Jagannath - Tisch Cancer Institute, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
https://touchoncologyime.org/eo-in-rrmm

102 episod

#Science #TouchPODCAST